{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:22:06Z","timestamp":1790043726566,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.bcmd.2011.04.005","type":"journal-article","created":{"date-parts":[[2011,5,6]],"date-time":"2011-05-06T12:42:16Z","timestamp":1304685736000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction"],"prefix":"10.1016","volume":"47","author":[{"given":"Deborah","family":"Elstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Joseph","family":"Foldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zahrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costin","family":"Brutaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2011.04.005_bb0005","series-title":"Williams Hematology","first-page":"1065","article-title":"Lipid storage diseases","author":"Zimran","year":"2010"},{"key":"10.1016\/j.bcmd.2011.04.005_bb0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0950-3536(97)80041-8","article-title":"Skeletal involvement in Gaucher's disease","volume":"10","author":"Elstein","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0015","unstructured":"E. Beutler and G.A. Grabowski, Gaucher disease, Editors: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, Associate Editors: B. Childs, K.W. Kinzler, B. Vogelstein, The Metabolic and Molecular Bases of Inherited Disease, 8th edition, McGraw-Hill, New York, 2001, Chapter 146 pp. 3635\u20133668. ISBNs 0-070913035-6; 07016319-X (Vol 1); 0-07016320-3 (Vol 2); 0-07016321-X (Vol 3); 0-07016322-X (Vol 4)."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008814105603","article-title":"The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study","volume":"7","author":"Damiano","year":"1998","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Quality of life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0030","first-page":"472","article-title":"Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease","volume":"11","author":"Pastores","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.bcmd.2011.04.005_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.bcmd.2011.04.005_bb0045","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.04.005_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0055","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","article-title":"Bone density in Type 1 Gaucher disease","volume":"11","author":"Pastores","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0060","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"Laird","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.bcmd.2011.04.005_bb0065","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group","author":"World Health Organization","year":"1994"},{"key":"10.1016\/j.bcmd.2011.04.005_bb0070","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.96.4.629","article-title":"Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase","volume":"96","author":"Rosenthal","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.bcmd.2011.04.005_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10545-010-9071-0","article-title":"Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment","volume":"33","author":"Piran","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0110","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2011.04.005_bb0115","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:28Z","timestamp":1761049708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979611000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1079979611000994"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.04.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}